• Science and Research

  Europe Gives Nod to Possible Approval of Vertex’s Triple Combo Therapy for 90% of CF Patients

  Posted by cystic-fibrosis-news-moderator on November 14, 2019 at 12:03 pm

  

  European regulators have validated Vertex’s request for approval of elexacaftor, tezacaftor, and ivacaftor, a next-gen combo for all with one F508del mutation. Read the full story here.

  What do you think of this news?

  cystic-fibrosis-news-moderator replied 4 years, 5 months ago 1 Member · 0 Replies
• 0 Replies

Log In to Reply